Immunogen, Inc. (NASDAQ: IMGN) reported Q2 EPS of ($0.17), $0.06 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $7.6 million versus the consensus estimate of $5.43 million.

For earnings history and earnings-related data on Immunogen, Inc. (IMGN) click here.

Earnings